Bilal A Siddiqui, MD

Peer-Reviewed Articles

1. # MS, # FE, Cruz CC, Machado AP, Mathew A, Zhao D, Siddiqui BA, Thomas AS, Chari ST, Wang Y. Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition. Target Oncol, 2025. e-Pub 2025. PMID: 40038186.
2. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
3. Storey CM, Cheng M, Altai M, Park JE, Tran J, Lueong SS, Thorek D, Mao L, Zedan W, Yuen C, Ridley A, Trajovic-Arsic M, Herrmann K, Subuhdi SK, Siddiqui BA, Luckerath K, Siveke J, Damoiseaux R, Yang X, Ulmert D. Key Regulatory Elements of the TGFbeta-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types. bioRxiv, 2024. e-Pub 2024. PMID: 39651139.
4. Ali A, Lu Y, Khalaf S, Iliescu C, Koutroumpakis E, Yusuf SW, Siddiqui BA, Subudhi SK, Deswal A, Palaskas NL. Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. J Nucl Cardiol 39:101909, 2024. e-Pub 2024. PMID: 39053574.
5. Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth RA, Tummala S, Buja M, Bhattacharjee MB, Iliescu C, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res 12(8):964-987, 2024. e-Pub 2024. PMID: 38768394.
6. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis, 2024. e-Pub 2024. PMID: 39019979.
7. Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw 22(5):1-8, 2024. e-Pub 2024. PMID: 38190801.
8. Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers (Basel) 15(24), 2023. e-Pub 2023. PMID: 38136389.
9. Pizuorno Machado A, Shatila M, Glitza Oliva IC, Altan M, Siddiqui BA, Zhou Y, Varatharajalu K, Zhang HC, Thomas A, Wang Y. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am J Clin Oncol 46(8):360-365, 2023. e-Pub 2023. PMID: 37219360.
10. Thomas AR, Liu C, Tong YT, Tan D, Altan M, Siddiqui BA, Shatila M, Khan A, Thomas AS, Wang Y. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol 149(8):5429-5436, 2023. e-Pub 2023. PMID: 36451045.
11. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor. J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
12. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34663638.
13. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Maximilian Buja L, Iliescu C. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 23(10):1725-1735, 2021. e-Pub 2021. PMID: 34114291.
14. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
15. Lehner MJ, Gheeya JS, Siddiqui BA, Tummala S. Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients. J Neurooncol 153(3):441-446, 2021. e-Pub 2021. PMID: 34076832.
16. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
17. Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33327406.
18. Hou, T, Sheu, TC, Campbell, MT, Subudhi, SK, Gao, J, Goswami, S, Siddiqui, BA, Palaskas, NL, Durand, JB, Tan, D. Histopathological Characteristics in Autoimmune Myocarditis Associated with Pembrolizumab: A Case Report and Literature Review. Journal of Cancer Science & Therapy 11(6):198-202, 2019. e-Pub 2019.
19. Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22, 2018. e-Pub 2018. PMID: 30083595.
20. Spencer AK, Siddiqui BA, Thomas JH. Cell shape change and invagination of the cephalic furrow involves reorganization of F-actin. Dev Biol 402(2):192-207, 2015. e-Pub 2015. PMID: 25929228.
21. Stern JN, Yaari G, Vander Heiden JA, Church G, Donahue WF, Hintzen RQ, Huttner AJ, Laman JD, Nagra RM, Nylander A, Pitt D, Ramanan S, Siddiqui BA, Vigneault F, Kleinstein SH, Hafler DA, O'Connor KC. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 6(248):248ra107, 2014. e-Pub 2014. PMID: 25100741.
22. Siddiqui BA. 2011 runner-up essay: stuffing mouths with gold: equitable solutions to the primary care physician shortage. Virtual Mentor 14(12):977-83, 2012. e-Pub 2012. PMID: 23351946.

Invited Articles

1. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
2. Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CJ, Frigo DE. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology 164(6), 2023. e-Pub 2023. PMID: 37192413.
3. Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
4. Siddiqui BA, Zhang M, Pisters LL, Tu SM. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol 9(Suppl 1):S56-S65, 2020. e-Pub 2020. PMID: 32055486.

Other Articles

1. Fang AM, MacDonald LP, Gregg JR, Siddiqui BA, Tang C, Chapin BF Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials. Curr Opin Urol 35(2):171-177, 2025. PMID: 39604252.
2. Gajagowni S, Wang E, Wang J, Campbell MT, Siddiqui BA Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT). Case Rep Oncol Med 2025:5582848, 2025. PMID: 39816730.
3. Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(5):617-618, 2024. PMID: 38642282.
4. Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Soroush-Rais-Bahrami, Bathala T, Chapin BF Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(1):66-83, 2024. PMID: 38212510.
5. Siddiqui B, Greka A, Popovtzer M, Rennke HG, Jeselsohn R Immune Complex-Mediated Proliferative Glomerulonephritis Induced by Paclitaxel Treatment. J Oncol Pract 12(12):1272-1274, 2016. PMID: 27845869.
6. Siddiqui AA, Siddiqui BA, Ganley-Leal L Schistosomiasis vaccines. Hum Vaccin 7(11):1192-7, 2011. PMID: 22048120.

Editorials

1. Palaskas NL, Siddiqui BA, Deswal A. Steroids in Immune Checkpoint Inhibitor Myocarditis. JACC CardioOncol 6(5):800-803, 2024. PMID: 39479336.
2. Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 19;3(4):100613, 2022. PMID: 35492243.
3. Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. PMID: 35290784.

Abstracts

1. Siddiqui BA, Zhang J, Carneiro BA, Zarrabi KK, Stein MN, Wise DR, Gelmann EP, C-K T, Falchook G, Kim JW, Gao X, Twardowski PW, Rana D, Fang F, Govindraj S, Sims JS, Skokos D, Seebach FA, Lowy I, Thanigaimani P, Ingham M, Sandigursky S, Miller E. Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). American Association for Cancer Research (AACR) Annual Meeting 2025. e-Pub 2025.
2. Kelly W, Srinivas S, Maly J, Kilari D, Hussain A, Saraiya B, Siddiqui BA, Monk P, Chatta G, Narayan V, Rana D, Thanigaimani P, Fang F, Skokos D, Kirshner J, Seebach F, Lowy I, Ingham M, Sandigursky S, Miller E. Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2025 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2025. e-Pub 2025.
3. He H, Gajagowni S, Varughese S, Ren W, Jan A, Wang E, Rawther-Karedath A, Jonasch E, Campbell M, Subudhi S, Alhalabi O, Siddiqui BA. Patterns of hospital admissions and readmissions due to immune-related adverse events in patients with genitourinary cancers, 2025. e-Pub 2025.
4. Siddiqui BA, Carneiro B, Stein M, Zhang J, Kelly W, Wise D, Tsao K, Falchook G, Twardowski P, Gao X, Kim J, Gelmann E, Thanigaimani P, Fang F, Seebach F, Lowy I, Ingham M, Kinnaman M, Sandigursky S, Miller E. A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). 2025 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium. e-Pub 2025.
5. Sherry A, Haymaker C, Fellman B, Bathala T, Medina-Rosales M, Liu S, Chun S, Mayo L, Choi S, Phillips R, Deek M, Aparicio A, Zurita A, Pilié P, Siddiqui BA, Subudhi S, Reuben A, Corn P, Tran P, Tang C. Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives. 2025 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2025. e-Pub 2025.
6. Venkatesh N, Chauhan P, Grewal K, Aparicio A, Pilié P, Subudhi S, Corn P, Siddiqui BA, Zurita A, Frigo D, Logothetis CJ, Msaouel P, Koutroumpakis E, Hahn AW. Evaluating clinical tools to monitor cardiovascular (CV) risk in men with localized high-risk or locally advanced prostate cancer (LHRPC) treated with hormone therapy (HT). 2025 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2025. e-Pub 2025.
7. Siddiqui BA, Chapin BF, Basu S, Jindal S, Zhang M, Troncoso P, Zhu K, Sandigursky S, Miller E, Skokos D, Simms J, Mezzancello M, Seebach F, Lowy I, Tidwell RS, Soule H, Sharma P, Subudhi SK. A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
8. Ostos-Mendoza K, Chen L, Lopez-Rodriguez A, Ali A, Siddiqui BA, Subudhi SK, Deswal A, Palaskas NL. Neuromuscular Immune-Related Adverse Events and Diaphragmatic Insufficiency as Mortality Predictors in Immune Checkpoint Therapy Associated Myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
9. Medina Rosales M, Sherry A, Lu X, Ludmir E, Reddy J, Woodward W, Msaouel P, Tannir N, Subudhi SK, Siddiqui BA, Corn P, Tang C, Haymaker C. Defining Circulating Myeloid Cell Phenotypic States in Patients with Oligometastatic Cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
10. Wang E, Jan A, Rawther-Karedath A, Nguyen-Paningbata A, Lim Z, Campbell M, Subudhi SK, Siddiqui, BA. Outcomes of a Pilot Educational Program for Frontline Clinical Staff in Early Detection and Intervention in Immune-Related Adverse Events. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
11. Gajagowni S, Rawther-Karedath A, Varughese S, Ren W, Jan A, Wang E, Grana A, Chen A, Cauley D, Campbell M, Alhalabi O, Cao H, Siddiqui BA, Subudhi SK. Core needle biopsy for diagnosis of immune-mediated myositis. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
12. Chen L, Ostos-Mendoza K, Palaskas N, Siddiqui BA, Subudhi SK. Immune checkpoint therapy (ICT) rechallenges after immune-mediated myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, 2024. e-Pub 2024.
13. Siddiqui BA, Chapin BF, Basu S, Jindal S, Zhang M, Troncoso P, Zhu K, Sandigursky S, Miller E, Skokos D, Simms J, Mezzancello M, Seebach F, Lowy I, Tidwell RS, Soule H, Sharma P, Subudhi SK. A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy. 31st Annual Prostate Cancer Foundation Scientific Retreat, 2024. e-Pub 2024.
14. Siddiqui BA, Datar S, Kravets A, Kudryavtseva K, Bagaev A, Yakimova D, Barykin E, Clayton P, Rusinov A, Hensley M, Basu S, Jindal S, Allison J, Sharma P, Subudhi SK. Baseline tumor extrinsic and intrinsic factors contributing to response to Anti-CTLA-4 in patients with metastatic castration-resistant prostate cancer (mCRPC). CRI-ENCI Eighth International Cancer Immunotherapy Conference, 2024. e-Pub 2024.
15. Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth R, Tummala S, Buja LM, Bhattacharjee M, Iliescu CA, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis. 5th Annual Management of Checkpoint Inhibitory Toxicity Meeting, 2024. e-Pub 2024.
16. Venkatesh N, Tidwell R, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Gregg JR, Corn PG, Msaouel P, Koutrompakis E, McQuade JL, Frigo D, Pilie PG, Logothetis C, Huff C, Hahn AW. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2024. e-Pub 2024.
17. Moussa MJ, Naqvi S, Khandelwal J, Campbell MT, Aparicio A, Siddiqui BA, Bryce A, Singh P, Alahalbi O. Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience. American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2024.
18. Siddiqui BA, Martiniova L, Kravets A, Clayton P, Hensley M, Bagaev A, Almog N, Ravizzini G, Logothetis CJ, Subudhi SK. Clinical Outcomes at a Single Institution with PSMAxCD28 T Cell Bispecific plus Anti-PD-1 in Patients with Metastatic Castration-Resistant Prostate Cancer. 30th Annual Prostate Cancer Foundation Scientific Retreat, 2023. e-Pub 2023.
19. Siddiqui BA, Palaskas NL, Basu S, He Z, Yadav SS, Duan F, Allison JP, Sheth R, Buja LM, Bhattacharjee M, Iliescu CA, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Hallmarks of immune checkpoint therapy-induced myocarditis and myositis. International Cancer Immunotherapy Conference (CICON) 2023, 2023. e-Pub 2023.
20. Siddiqui BA, Palaskas N, Basu S, He Z, Sheth R, Buja M, Bhattacharjee M, Mancuso J, Fu T, Iliescu C, Deswal A, Rawther-Karedath A, Yadav SS, Allison JP, Sharma P, Subudhi SK. Identifying molecular targets for rational immunosuppressive strategies in severe immune checkpoint therapy (ICT)-induced myocarditis and myositis. American Society for Clinical Oncology (ASCO) Annual Meeting 2023, 2023. e-Pub 2023.
21. Caldwell R, Pina G, Oderinde P, Ali A, Garrett J, Siddiqui BA, Subudhi SK, Iliescu C, Yusuf SW, Koutroumpakis E, Hamzeh E, Khalaf S, Deswal A, Palaskas NL. Elevated serum TNF-α is a candidate prognostic biomarker for immune checkpoint inhibitor myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2022. e-Pub 2022.
22. Hahn AW, Siddiqui, BA, Logothetis CJ, Subudhi SK, Corn PG, Pilie P, Zurita AJ, Aparicio AM, Tidwell, R S, Thoman, W, Abdulla, A, Koutroumpakis, E, Laccetti, A L, Jana, B, Basen-Engquist, K. A phase II trial modifying metabolic syndrome and cardiovascular risk for prostate cancer patients on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio). American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2022. e-Pub 2022.
23. Palaskas NL, Lu Y, Caldwell R, Oderinde P, Pina G, Ali A, Shah K, Iliescu C, Yusuf SW, Koutroumpakis E, Khalaf S, Hamzeh I, Siddiqui BA, Subudhi SK, Deswal A. Use of positron emission tomography for the diagnosis of immune checkpoint inhibitor myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2022. e-Pub 2022.
24. Siddiqui BA, Palaskas N, Sheth R, Basu S, Tummala S, Lu HL, Hosing C, Rawther-Karedath A, Yadav SS, Sharma P, Subudhi SK. Identifying molecular targets for rational immunosuppressive strategies in severe immune checkpoint therapy (ICT)-induced myocarditis, myositis, and myasthenia gravis (MG). International Cancer Immunotherapy Conference (CICON) 2022, 2022. e-Pub 2022.
25. Subudhi SK, Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Pettaway C, Ward JF, Tidwell RS, Corn PG, Logothetis CJ, Knoblauch RE, Hutnick NA, Gottardis MM, Drake CG, Allison JP, Sharma P. Daratumumab (Anti-CD38) But Not Edicotinib (CSF-1R Inhibitor) Demonstrates Target Engagement Within the Primary Prostate Cancer, Bone Marrow and Systemic Circulation of Patients with Localized Disease. International Cancer Immunotherapy Conference (CICON) 2022, 2022. e-Pub 2022.
26. Palaskas NL, Siddiqui BA, Shah K, Koutroumpakis E, Iliescu C, Subudhi SK, Deswal A. Upfront immunomodulatory treatment of immune checkpoint inhibitor myocarditis. American College of Cardiology (ACC) Annual Meeting, 2022. e-Pub 2022.
27. Hahn AW, Wang X, Efstathiou E, Hwang H, Zurita AJ, Wang J, Araujo JC, Pilie P, Siddiqui BA, Subudhi SK, Corn PG, Aparicio AM, Tu SM, Logothetis CJ. Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone naïve prostate cancer (M0HNPC). American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2022. e-Pub 2022.
28. Siddiqui BA, Chapin BF, Jindal S, Duan F, Yadav SS, Pettaway C, Ward JF, Tidwell RS, Corn PG, Logothetis CJ, Allison JP, Sharma P, Subudhi SK. Target Modulation within the Tumor Microenvironment (TME) by Daratumumab (anti-CD38) but not Edicotinib (CSF-1R inhibitor) in Men with High-Risk Localized Prostate Cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2021. e-Pub 2021.
29. Subudhi SK, Siddiqui BA, Maly JJ, Nandagopal L, Lam E, Whang YE, Minocha M, Gupta V, Penny X, Cooner F, Jhones C, Paluch A, Salvati M, Janat-Amsbury M, Eggert T, Kouros-Mehr H, Joshua AM, Aggarwal RR, De Bono JS. Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC). American Society for Clinical Oncology (ASCO), 2021. e-Pub 2021.
30. Siddiqui BA, Gheeya JS, Goswamy R, Subudhi SK, Gao JJ, Campbell MT, Shah AY, Msaouel P, Zurita AJ, Goswami S, Wang J, Jonasch E, Siefker-Radtke A, Sharma P, Tannir NM. Immune Checkpoint Therapy (ICT) Re-challenge after Immune-Related Adverse Events (irAEs) in Genitourinary Cancers (GUC). European Society for Medical Oncology (ESMO) Virtual Conference, 2020. e-Pub 2020.
31. Hwang MJ, Siddiqui BA, Merriman KW, Uthup J, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang, M, Tu SM. Origin of a second malignancy harboring isochromosome 12p [i(12p)] in patients with history of testicular germ cell tumor (TGCT). American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium, 2020. e-Pub 2020.
32. Siddiqui BA, Gheeya JS, Tummala S. Paraneoplastic cerebellar degeneration (PCD) associated with PCA-1 antibodies, unfolding of syndrome in established cancer patients. Society for Nuero Oncology (SNO) Annual Meeting, 2020. e-Pub 2020.
33. Siddiqui BA, Thompson TC, Pilie PG, Logothetis CJ, Aparicio AM, Subudhi SK. Resistance to Immune Checkpoint therapy (ICT) in Aggressive Variant Prostate Cancer (AVPC). 13th Annual Multi-Institutional Prostate Cancer Program Retreat, 2020. e-Pub 2020.
34. Umbreit E, Hwang M, Westerman MB, Siddiqui BA, Zhang M, Karam J, Wood C, Tu SM. MP11-18: Origin of a second malignancy harboring isochromosome 12p in patients with history of testicular germ cell tumor (TGCT). American Urological Association Annual Virtual Meeting, 2020. e-Pub 2020.
35. Msaouel P, Van Alstine ML, Oromendia C, Gao JJ, Wang Y, Siddiqui BA, Siefker-Radtke AO, Shah AY, Shaw L, Lopez L, Laccetti AL, Tannir NM, Elashoff M, Logothetis C. Technology-Enabled Longitudinal Monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs). American Society for Clinical Oncology (ASCO) Annual Virtual Meeting, 2020. e-Pub 2020.
36. Siddiqui BA, Durand JB, Gao JJ, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Suarez-Almazor ME, Sudhakar T, Logothetis CJ, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. American Society for Clinical Oncology (ASCO) Annual Meeting, 2019. e-Pub 2019.
37. Siddiqui BA, Palaskas N, Durand JB, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Tummala S, Bhattacharjee M, Logothetis CJ, Tannir NM, Sharma P, Subudhi SK. Clinical and Immunologic Features of Immune Checkpoint Therapy (ICT)-Associated Neuromuscular and Cardiac Toxicities. 3rd Annual Global Summit on Genitourinary Malignancies, 2019. e-Pub 2019.
38. Siddiqui BA, Matos JD, Moran J. Septic shock and massive intravascular hemolysis: a toxic case. New England Regional Meeting of the Society of General Internal Medicine, 2017. e-Pub 2017.
39. Kuang Y, Siddiqui, BA, Hu J, Barry W, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy. American Association for Cancer Research (AACR) Annual Meeting, 2017. e-Pub 2017.
40. Siddiqui BA, Hale AJ. Chronic cough in a healthy 27-year-old man as the presenting feature of massive anterior mediastinal metastatic seminoma. New England Regional Meeting of the Society of General Internal Medicine, 2016. e-Pub 2016.

Book Chapters

1. Sharma, P, Anandhan, S, Siddiqui, BA, Goswami, S, Sharma, A, Subudhi, SK, Gao, JJ, Peggs, K, Quezada, S, Allison, JP. Cancer Immunotherapy. In: Cancer Medicine. 10th. Wiley-Blackwell, 2023.
2. Siddiqui BA, Goswami S, Allison JP, Sharma P. Immuno-Oncology. In: In: The MD Anderson Manual of Medical Oncology. 4th Edition. McGraw Hill, 2022.
3. Roberts, R, Siddiqui, BA, Subudhi, SK, Sheth, RA. Image-Guided Biopsy/Liquid Biopsy. In: Image-Guided Interventions in Oncology. Springer, 2020.